MD News and Information

Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial

Author: H. Ghofrani, F. Grimminger, E. Grünig, Y. Huang, et al
Date Published: April-2016
Source: The Lancet

Pulmonary arterial hypertension is a chronic disease associated with poor long-term outcomes. Identifying predictors of long-term outcome in pulmonary arterial hypertension is important to assess disease severity and guide treatment. We investigate associations between efficacy parameters and long-term outcomes in patients with pulmonary arterial hypertension receiving riociguat in the PATENT-2 study. We also present safety and efficacy data from the final data cutoff of PATENT-2, where most patients had received at least 2 years of riociguat treatment.


Large Scleroderma Study Offers Genetic Map, Identifies Patients at Risk for Pulmonary Hypertension

Author: Margarida Azevdeo
Date Published: April-2016
Source: Scleroderma News Today

A research team with scientists from the University of Granada in Spain and the Spanish National Research Council (CSIC) has carried out the largest scleroderma study to date, creating a complete genetic map of the disease with the genetic analysis of more than 5,000 patients.


FDA Approves Corbus Phase 2 Trial Extension of Systemic Sclerosis Drug Resunab

Author: Kara Elam
Date Published: April-2016
Source: Lung Disease News

Corbus Pharmaceuticals, a clinical stage company targeting rare, chronic inflammatory and fibrotic diseases, recently received approval by the U.S. Food and Drug Administration (FDA) for a 12-month open-label extension trial of the ongoing Phase 2 study testing Resunab as a therapy for diffuse cutaneous systemic sclerosis.


Cardiovascular Focus: Scleroderma Presentations from FESCA

Author: FESCA
Date Published: February-2016
Source: 4th Systemic Sclerosis World Congress

In the nearly hour-long video, linked below, several engaging experts detail the ways that scleroderma can impact cardiovascular function. Professor Oliver Distler, University Hospital Zurich, brings participants through pulmonary changes arising from fibrosis, detailing testing regimen, and identifying targets for anti-fibrotic medications in clinical trials.


Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis

Author: Rucsandra Dobrota, Britta Maurer1, Nicole Graf, Suzana Jordan, Carina Mihai, Otylia Kowal-Bielecka, Yannick Allanore, Oliver Distler
Date Published: March-2016
Source: Annals of the Rheumatic Diseases

Improvement of skin fibrosis is part of the natural course of diffuse cutaneous systemic sclerosis (dcSSc). Recognising those patients most likely to improve could help tailoring clinical management and cohort enrichment for clinical trials. In this study, we aimed to identify predictors for improvement of skin fibrosis in patients with dcSSc.


Muscle Weakness Predicts Disability in Scleroderma

Author: Wayne Kuznar
Date Published: March-2016
Source: MedPage Today

Muscle weakness was independently associated with disability in patients with scleroderma, and as muscle weakness worsened, disability also increased, according to findings from a retrospective, nested, case control study. Patients with muscle weakness had an average Health Assessment Questionnaire-Disability Index (HAQ-DI) of 1.4, which indicates moderate to severe disability, according to Julie J. Paik, MD, MHS, and colleagues from Johns Hopkins University in Baltimore.

<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 8 of 21